Document is current
Any future updates will be listed below
-
Authors
Viergever, Bastiaan J.
Raats, Daniëlle A. E.
Geurts, Veerle
Mullenders, Jasper
Jonges, Trudy N.
van der Heijden, Michiel S. https://orcid.org/0000-0002-4407-7881
van Es, Johan H.
Kranenburg, Onno https://orcid.org/0000-0002-2112-4390
Meijer, Richard P. https://orcid.org/0000-0003-2510-7982
-
Funding
Funding for this research was provided by:
Astellas Pharma Europe
- License Information
-
More Information
Article History
Received: 15 March 2023
Revised: 27 October 2023
Accepted: 6 November 2023
First Online: 15 December 2023
Ethics approval and consent to participate
: Bladder cancer patients from the University Medical Center Utrecht were invited to participate in this prospective proof-of-concept project by means of informed consent by the treating urologist or the nurse practitioner. Human bladder tissue was obtained from the University Medical Center Utrecht (UMCU). Ethical approval was granted by the Biobank Research Ethics Committee (TCBio) of the UMCU. Written informed consent was obtained from all patients involved in this project.
: BV: Research support (institutional): Janssen Pharmaceuticals, Astellas Pharmaceuticals. DR: Research support (institutional): Janssen Pharmaceuticals, Astellas Pharmaceuticals. VG, JE, TJ and JM declare no competing interests. MH: Research support from Bristol-Myers Squibb, AstraZeneca, Roche and 4SC; consultancy fees from Bristol-Myers Squibb, Merck, Roche, AstraZeneca, Seagen, Pfizer and Janssen (all paid to the Netherlands Cancer Institute). OK: Research support (institutional): Janssen Pharmaceuticals, Astellas Pharmaceuticals. RM: Advisory role (institutional): Merck, MSD, Janssen, Bristol-Myers Squibb. Research support (institutional): Janssen Pharmaceuticals, Astellas Pharmaceuticals.
